Bronchodilators Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2025
- Transparency Market Research
Bronchodilators are drugs used by people suffering with asthma. These drugs help open the airway passages. These are also used for expanding the wind pipe, thus improving the breathing of the individuals suffering from lung infections, bronchial asthma, and chronic obstructive pulmonary disease (COPD).
There are two forms of bronchodilators: short acting bronchodilators and long acting bronchodilators. The short acting bronchodilators provide quick relief from asthma and can be used on a daily basis. The long acting bronchodilators assist in controlling the symptoms of asthma by opening the air passage for up to 12 hours. Short acting bronchodilators include albuterol (a generic solution for nebulizers), metaproterenol, pirbuterol, and levalbuterol. Long acting bronchodilators include advair, symbicort, and dulera which is a combination of beta agonist bronchodilator and a steroid. Major side effects of bronchodilators include increased heart rate, muscle cramps, inappropriate sleeping pattern, upset stomach, and others. According to the Centers for Disease and Control of Infection reports published in 2014, the number of adults who were diagnosed with asthma was 17.7 million, out of which, there were 3,651 deaths due to asthma, and women were the most affected. According the World Health Organization, in 2012, more than three million people died due to COPD, which was 6% of all deaths globally.
There are three types of bronchodilator used for treating respiratory diseases: beta-agonist, anticholinergic, and theophylline. These types are available in different forms based on route of administration such as inhaler, tablet, liquid, and injectable. Inhaler is the most preferred form of administration for using beta-agonist and anticholinergic. A major disadvantage of long acting beta agonist bronchodilator is that it increases the risk of asthma death; therefore, it should be used only as an added treatment for individuals or patients who use steroid. Anticholinergics are used for treating patients suffering from COPD and asthma. Atrovent, an anticholinergic bronchodilator, is used for the treatment of COPD. It is administered using an inhaler or a nebulizer. Tiotropium bromide is a long acting anticholinergic inhaler, which is used for treating patients suffering from asthma and COPD.
The global bronchodilators market has been segmented based on form of bronchodilator, route of administration, drug class, distribution channel, and region. In terms of form of bronchodilator, the global market is divided into short acting bronchodilators and long acting bronchodilators. Based on route of administration, the market is segmented into oral, injectable, and nasal. In terms of drug class, the market is divided into adrenergic bronchodilators, anticholinergic bronchodilators, and others.
The major drivers for the growth of the global bronchodilators market are rising incidence rate of respiratory and pulmonary diseases such as asthma and COPD, growing awareness among individuals, increasing initiatives by governments and health care services, increasing demand for bronchodilator drugs, and adoption of unhealthy lifestyle. According to WHO reports, there is an increased use of tobacco among women in high-income countries and increased risk of exposure to indoor air pollutants in low-income countries. COPD affects men and women equally. The global burden of COPD was nearly 251 million cases in 2016. The WHO has designed a framework named WHO Framework Convention on Tobacco Control (WHO FCTC) to implement MPOWER package, which aims at assisting country level implementation of effective interventions focused on reducing the demand for tobacco.
Geographically, the global bronchodilators market is distributed over North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is expected to be the largest market for bronchodilators due to high incidence rate of diseases such as COPD and asthma, high demand for bronchodilator drugs, and increase in awareness. Europe holds the second largest market share. The Asia Pacific market is expected to provide a lucrative opportunity during the forecast period due to increasing disease burden, growing biopharmaceutical industry, and rising research activity along with competitive landscape in the pharmaceutical industry. The market in Latin America and Middle East & Africa is anticipated to grow owing to increasing health care infrastructure and growing public-private collaboration to expand the health care sector.
Major companies operating in the global bronchodilators market are F. Hoffmann-La Roche, Gilead Sciences, Novartis Ag, Boehringer Ingelheim, GlaxoSmithKline, Merck & Co., Inc., and AstraZeneca.
The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.
The study is a source of reliable data on:
- Market segments and sub-segments
- Market trends and dynamics
- Supply and demand
- Market size
- Current trends/opportunities/challenges
- Competitive landscape
- Technological breakthroughs
- Value chain and stakeholder analysis
The regional analysis covers:
- North America (U.S. and Canada)
- Latin America (Mexico, Brazil, Peru, Chile, and others)
- Western Europe (Germany, U.K., France, Spain, Italy, Nordic countries, Belgium, Netherlands, and Luxembourg)
- Eastern Europe (Poland and Russia)
- Asia Pacific (China, India, Japan, ASEAN, Australia, and New Zealand)
- Middle East and Africa (GCC, Southern Africa, and North Africa)
The report has been compiled through extensive primary research (through interviews, surveys, and observations of seasoned analysts) and secondary research (which entails reputable paid sources, trade journals, and industry body databases). The report also features a complete qualitative and quantitative assessment by analyzing data gathered from industry analysts and market participants across key points in the industry’s value chain.
A separate analysis of prevailing trends in the parent market, macro- and micro-economic indicators, and regulations and mandates is included under the purview of the study. By doing so, the report projects the attractiveness of each major segment over the forecast period.
Highlights of the report:
- A complete backdrop analysis, which includes an assessment of the parent market
- Important changes in market dynamics
- Market segmentation up to the second or third level
- Historical, current, and projected size of the market from the standpoint of both value and volume
- Reporting and evaluation of recent industry developments
- Market shares and strategies of key players
- Emerging niche segments and regional markets
- An objective assessment of the trajectory of the market
- Recommendations to companies for strengthening their foothold in the market
Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.
Have query on this report?Make an Enquiry
The team was the biggest help to us. Not only were we provided with customized solutions but also we were guided through the most complicated situations. The information was on-point yet comprehensive. The experience was absolutely satisfying and helped us turn many challenges into opportunities.
Ours is a startup with a unique set of challenges and we were therefore hesitant but the team totally put us at ease with their knowledge and expertise. Our business and its challenges were understood perfectly and help was extended accordingly. The tailor made approach really helped us gain the most informative insights.
The report repository is absolutely impressive –updated and exhaustive in terms of markets covered and information provides. Besides, with the support extended to us by the team, we could reduce costs as well as move to sustainable growth. This really helped us tap into new opportunities. Happy to have gone ahead with ResearchMos.us.
We have had a long term engagement with ResearchMoz.us and never have we felt that the work done and help extended were below flawless. The report repository is one of the best one can hope to tap into. Recently, our partner businesses opted for consultancy services and they are all thrilled with the outcome.
Insights from reports helped us improve our profit margins significantly. Most of the knowledge we needed on the market were provided to us on a granular basis. From trends, and drivers to competitive analysis, the information was not just crisp but also insightful. That helped us chart a robust growth strategy and as of now we are happy to state that we are reaping big benefits.
More from Pharmaceutical
PharmaceuticalChinese Markets for Mental Illness Drugs
PharmaceuticalChinese Markets for Anti-Dermatomycosis Skin Drugs
PharmaceuticalChinese Markets for Incretion Drugs
PharmaceuticalChinese Markets for Hypertension Drugs
Pharmaceuticals and HealthcareGlobal Bionic Ears Market Professional Survey Report 2017
Pharmaceuticals and HealthcareNeuropsychiatric Disorder Cluster Drug Development Pipeline Review, 2017
Pharmaceuticals and HealthcareHepatitis Drug Development Pipeline Review, 2017